Sulfonylureas may increase risk of death in type 2 diabetes patients

09/26/2013 | U.S. News & World Report

British researchers found type 2 diabetes patients who used sulfonylureas as an initial treatment had a 58% higher risk of all-cause mortality compared with those who were on metformin monotherapy. While more data are needed, the results suggest using sulfonylureas as first-line monotherapy "should be reconsidered," researchers reported at the European Association for the Study of Diabetes meeting.

View Full Article in:

U.S. News & World Report

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID